Viatris (VTRS) Change in Account Payables (2020 - 2026)
Viatris' (VTRS) quarterly Change in Account Payables came in at $32.7 million in Q1 2026, down 67.81% year-on-year from $101.6 million in Q1 2025, and up 76.76% quarter-over-quarter from $18.5 million in Q4 2025.
Viatris (VTRS) Change in Account Payables (2020 - 2026) Analysis & Trends
Viatris' Change in Account Payables history runs 7 years deep, the most recent figure standing at $32.7 million for Q1 2026.
- On a quarterly basis, Change in Account Payables fell 67.81% year-over-year to $32.7 million in Q1 2026; TTM through Mar 2026 was -$236.9 million, a 57.62% decrease from a year earlier, with the FY2025 full-year figure at -$168.0 million, down 566.67% from the prior year.
- Change in Account Payables grew to $32.7 million in Q1 2026 per VTRS's latest filing, from $18.5 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $287.9 million in Q1 2024 and bottomed at -$329.9 million in Q3 2022.
- The 5-year median for Change in Account Payables is $32.7 million (2026), against an average of $22.7 million.
- Across the five-year window, Change in Account Payables surged 707.28% in 2023 and slumped 2590.32% in 2024, its largest moves.
- Year by year, Change in Account Payables stood at $245.6 million in 2022, then sank by 68.08% to $78.4 million in 2023, then tumbled by 41.71% to $45.7 million in 2024, then tumbled by 59.52% to $18.5 million in 2025, then soared by 76.76% to $32.7 million in 2026.
- Per Business Quant, the three latest VTRS Change in Account Payables figures stand at $32.7 million (Q1 2026), $18.5 million (Q4 2025), and $3.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.70 Mn |
| Mar 31, 2026 | 32.70 Mn |
| Dec 31, 2025 | 18.50 Mn |
| Dec 31, 2025 | 18.50 Mn |
| Sep 30, 2025 | 3.20 Mn |
| Sep 30, 2025 | 3.20 Mn |
| Jun 30, 2025 | -291.30 Mn |
| Jun 30, 2025 | -291.30 Mn |
| Mar 31, 2025 | 101.60 Mn |
| Mar 31, 2025 | 101.60 Mn |
| Dec 31, 2024 | 45.70 Mn |
| Dec 31, 2024 | 45.70 Mn |
| Sep 30, 2024 | -66.00 Mn |
| Sep 30, 2024 | -66.00 Mn |
| Jun 30, 2024 | -231.60 Mn |
| Jun 30, 2024 | -231.60 Mn |
| Mar 31, 2024 | 287.90 Mn |
| Mar 31, 2024 | 287.90 Mn |
| Dec 31, 2023 | 78.40 Mn |
| Dec 31, 2023 | 78.40 Mn |